[{"address1": "4000 Shoreline Court", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 822 5600", "website": "https://www.kezarlifesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 58, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher J. Kirk Ph.D.", "age": 51, "title": "Co-Founder, CEO & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 644685, "exercisedValue": 0, "unexercisedValue": 5485}, {"maxAge": 1, "name": "Mr. John Franklin Fowler", "age": 51, "title": "Co-Founder & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 539349, "exercisedValue": 0, "unexercisedValue": 2641}, {"maxAge": 1, "name": "Dr. Jack  Taunton Ph.D.", "title": "Co-Founder", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gitanjali  Jain", "title": "Senior Vice President of Investor Relations & External Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Schiller", "age": 43, "title": "Chief Legal Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joe  Tedrick", "title": "Vice President of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neel K. Anand Ph.D.", "title": "Senior Vice President of Research & Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Zung  To", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pattie  Chiang", "title": "Senior VP & Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.78, "open": 6.79, "dayLow": 6.72, "dayHigh": 6.96, "regularMarketPreviousClose": 6.78, "regularMarketOpen": 6.79, "regularMarketDayLow": 6.72, "regularMarketDayHigh": 6.96, "beta": 0.217, "forwardPE": -0.7293355, "volume": 28800, "regularMarketVolume": 28800, "averageVolume": 104975, "averageVolume10days": 78470, "averageDailyVolume10Day": 78470, "bid": 6.67, "ask": 6.81, "bidSize": 100, "askSize": 100, "marketCap": 49249484, "fiftyTwoWeekLow": 5.2, "fiftyTwoWeekHigh": 11.4, "priceToSalesTrailing12Months": 7.0356407, "fiftyDayAverage": 7.597, "twoHundredDayAverage": 7.28325, "currency": "USD", "enterpriseValue": -91923296, "floatShares": 4544087, "sharesOutstanding": 7296220, "sharesShort": 177961, "sharesShortPriorMonth": 98290, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.024400001, "heldPercentInsiders": 0.14795, "heldPercentInstitutions": 0.63899, "shortRatio": 0.93, "shortPercentOfFloat": 0.025, "impliedSharesOutstanding": 7296220, "bookValue": 25.773, "priceToBook": 0.26190197, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -98568000, "trailingEps": -13.12, "forwardEps": -10.47, "lastSplitFactor": "1:10", "lastSplitDate": 1730246400, "enterpriseToRevenue": -13.132, "enterpriseToEbitda": 0.934, "52WeekChange": -0.1964286, "SandP52WeekChange": 0.2764505, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "KZR", "underlyingSymbol": "KZR", "shortName": "Kezar Life Sciences, Inc.", "longName": "Kezar Life Sciences, Inc.", "firstTradeDateEpochUtc": 1529587800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "a58d540c-0082-3b09-9235-096cecf4e362", "messageBoardId": "finmb_304157325", "gmtOffSetMilliseconds": -18000000, "currentPrice": 6.75, "targetHighPrice": 18.0, "targetLowPrice": 11.0, "targetMeanPrice": 14.5, "targetMedianPrice": 14.5, "recommendationMean": 2.33333, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 164182000, "totalCashPerShare": 22.502, "ebitda": -98462000, "totalDebt": 17610000, "quickRatio": 9.481, "currentRatio": 9.581, "totalRevenue": 7000000, "debtToEquity": 11.687, "revenuePerShare": 0.962, "returnOnAssets": -0.28068, "returnOnEquity": -0.51477003, "freeCashflow": -41498624, "operatingCashflow": -79078000, "operatingMargins": -14.22014, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]